Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 19;9(7):841.
doi: 10.3390/biomedicines9070841.

Relationship between Circulating PCSK9 and Markers of Subclinical Atherosclerosis-The IMPROVE Study

Affiliations

Relationship between Circulating PCSK9 and Markers of Subclinical Atherosclerosis-The IMPROVE Study

Daniela Coggi et al. Biomedicines. .

Abstract

(1) Background and purpose: circulating proprotein convertase subtilisin/kexin type 9 (PCSK9) is one of the key regulators of cholesterol metabolism. Despite this, its role as a player in atherosclerosis development is still matter of debate. Here, we investigated the relationships between this protein and several markers of subclinical atherosclerosis. (2) Methods: the IMPROVE study enrolled 3703 European subjects (54-79 years; 48% men; with ≥3 vascular risk factors), asymptomatic for cardiovascular diseases. PCSK9 levels were measured by ELISA. B-mode ultrasound was used to measure markers of carotid subclinical atherosclerosis. (3) Results: in the crude analysis, PCSK9 levels were associated with several baseline measures of carotid intima-media thickness (cIMT) (all p < 0.0001); with cIMT change over time (Fastest-IMTmax-progr) (p = 0.01); with inter-adventitia common carotid artery diameter (ICCAD) (p < 0.0001); and with the echolucency (Grey Scale Median; GSM) of both carotid plaque and plaque-free common carotid IMT (both p < 0.0001). However, after adjustment for age, sex, latitude, and pharmacological treatment, all the afore-mentioned correlations were no longer statistically significant. The lack of correlation was also observed after stratification for sex, latitude, and pharmacological treatments. (4) Conclusions: in subjects who are asymptomatic for cardiovascular diseases, PCSK9 plasma levels do not correlate with vascular damage and/or subclinical atherosclerosis of extracranial carotid arteries.

Keywords: PCSK9; carotid artery; echolucency; intima-media thickness; subclinical atherosclerosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Examples of lesions with echolucent (A,B) and echo-rich (C,D) features of two types of carotid ultrasonographic images. Panels on the left show the echolucency features detected on the common carotid IMT, measured in plaque free areas (echolucency of PF CC-IMTmean). Panels on the right show the same features detected on a carotid plaque (echolucency of plaque).

References

    1. Horton J.D., Cohen J.C., Hobbs H.H. PCSK9: A convertase that coordinates LDL catabolism. J. Lipid Res. 2009;50:S172–S177. doi: 10.1194/jlr.R800091-JLR200. - DOI - PMC - PubMed
    1. Mousavi S.A., Berge K.E., Leren T.P. The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis. J. Intern. Med. 2009;266:507–519. doi: 10.1111/j.1365-2796.2009.02167.x. - DOI - PubMed
    1. Li S., Li J.-J. PCSK9: A key factor modulating atherosclerosis. J. Atheroscler. Thromb. 2015;22:221–230. doi: 10.5551/jat.27615. - DOI - PubMed
    1. Tang Z., Li T., Peng J., Zheng J., Li T., Liu L., Jiang Z., Zheng X.-L. PCSK9: A novel inflammation modulator in atherosclerosis? J. Cell. Physiol. 2019;234:2345–2355. doi: 10.1002/jcp.27254. - DOI - PubMed
    1. Leander K., Malarstig A., Hooft F.M.V., Hyde C., Hellénius M.-L., Troutt J.S., Konrad R.J., Öhrvik J., Hamsten A., De Faire U. Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors. Circulation. 2016;133:1230–1239. doi: 10.1161/CIRCULATIONAHA.115.018531. - DOI - PubMed